摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

iso-propyl 2-cyano-6-(3,4-difluorobenzoyl)-4,4-dimethyl-1,4,5,6,7,8-hexahydropyrrolo[2,3-d]azepine-8-carboxylate | 1155659-12-3

中文名称
——
中文别名
——
英文名称
iso-propyl 2-cyano-6-(3,4-difluorobenzoyl)-4,4-dimethyl-1,4,5,6,7,8-hexahydropyrrolo[2,3-d]azepine-8-carboxylate
英文别名
Isopropyl 2-cyano-6-(3,4-difluorobenzoyl)-4,4-dimethyl-1,4,5,6,7,8-hexahydropyrrolo[2,3-d]azepine-8-carboxylate;propan-2-yl 2-cyano-6-(3,4-difluorobenzoyl)-4,4-dimethyl-1,5,7,8-tetrahydropyrrolo[2,3-d]azepine-8-carboxylate
iso-propyl 2-cyano-6-(3,4-difluorobenzoyl)-4,4-dimethyl-1,4,5,6,7,8-hexahydropyrrolo[2,3-d]azepine-8-carboxylate化学式
CAS
1155659-12-3
化学式
C22H23F2N3O3
mdl
——
分子量
415.44
InChiKey
JTWLRQHGXNKRJB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    30
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    86.2
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
    申请人:Mehlmann John Francis
    公开号:US20090131409A1
    公开(公告)日:2009-05-21
    Disclosed are chemical entities including compounds of Formula I and pharmaceutically acceptable salts thereof, wherein X is chosen from CN, CF 3 , CF 2 H, S(O) n R 6 , and S(O) 2 N(R 9 )R 10 ; Y is chosen from CR 11 and N; Z is chosen from O and NH; R 3 is chosen from —C(O)R 12 and —C(O)N(R 9 )R 10 ; and n, R 1 , R 2 and R 4 -R 12 are defined herein; compositions comprising one or more such chemical entities; and methods of using one or more such chemical entities for modulating the activity of certain receptors (e.g., farnesoid X) or for the treatment or prevention of one or more symptoms of disease or disorder related to the activity of those receptors.
    本发明涉及化合物I式及其药学上可接受的盐,其中X选择自CN、CF3、CF2H、S(O)nR6和S(O)2N(R9)R10;Y选择自CR11和N;Z选择自O和NH;R3选择自—C(O)R12和—C(O)N(R9)R10;并且在此定义中n、R1、R2和R4-R12;包含一种或多种此类化学实体的组合物;以及使用一种或多种此类化学实体来调节某些受体(例如farnesoid X)的活性或治疗或预防与这些受体活性相关的一种或多种疾病或症状的方法。
  • Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR)
    作者:John F. Mehlmann、Matthew L. Crawley、Joseph T. Lundquist、Ray J. Unwalla、Douglas C. Harnish、Mark J. Evans、Callain Y. Kim、Jay E. Wrobel、Paige E. Mahaney
    DOI:10.1016/j.bmcl.2009.07.148
    日期:2009.9
    Pyrrole[2,3-d]azepines have been identified as potent agonists of the farnesoid X receptor (FXR). Based on the planar X-ray crystal structure of WAY-362450 1 in the ligand binding domain and molecular modeling studies, non-planar reduced compounds were designed which led to agonists that exhibit high aqueous solubility and retain moderate in vitro potency. (C) 2009 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

环戊二烯并[4,5]氮杂卓并[2,1,7-cd]吡咯里嗪 吡咯并[1,2-a]氮杂-5-酮 六氢-1H-吡咯并[1,2-A]氮杂卓-5(6H)-酮 N,N-二甲基-3-(3-甲基-1,2,4,5-四氢氮杂卓并[4,5-b]吲哚-6-基)丙-1-胺 9-氟-1,2,3,4,5,6-六氢氮杂卓并[4,5-b]吲哚 7,8-二氢-5H-吡咯并[1,2-A]氮杂环庚烷-9(6H)-酮 6-叔-丁基3A-乙基八氢吡咯并[2,3-D]氮杂卓-3A,6(2H)-二甲酸基酯 6,7-二氢吡咯并[2,3-c]氮杂卓-4,8(1H,5H)-二酮 5H-吡咯并[1,2-a]氮杂卓-7-醇 5,9:7,11-二亚甲基-5H-吡咯并[1,2-a]吖壬英-3-羧酸,6,7,8,9,10,11-六氢-,甲基酯 4-(2-氨基-1H-咪唑-5-基)-2,3-二溴-6,7-二氢吡咯并[2,3-c]氮杂卓-8(1H)-酮 4-(2-氨基-1H-咪唑-4-基)-2,3-二溴-4,5,6,7-四氢吡咯并[2,3-c]氮杂卓-8(1H)-酮 4-(2-氨基-1,5-二氢-5-氧代-4H-咪唑-4-亚基)-4,5,6,7-四氢-吡咯并[2,3-c]氮杂卓-8(1H)-酮 3-苄基-1,2,3,4,5,6-六氢氮杂卓并[4,5-b]吲哚 3-(3,9-二甲基-1,2,4,5-四氢氮杂卓并[4,5-b]吲哚-6-基)-N,N-二甲基丙烷-1-胺 2H,3H-氧杂环丁烷并[3,2-d]吡咯并[1,2-a]氮杂卓 2-溴-6,7-二氢-1h,5h-吡咯并[2,3-c]氮杂烷-4,8-二酮 2,5-已炔二醇 2,3,4,5-四氢-N,N-二甲基-2-(3,4,5-三甲氧基苯甲酰基)-氮杂卓并(3,4-b)吲哚-10(1H)-丙胺 11-氧杂-3,10-二氮杂三环[7.2.1.03,7]十二碳-1,4,6,9-四烯 1,4,5,6,7,8-六氢吡咯并[3,2-b]氮杂卓 1,2,3,4,5,6-六氢氮杂环庚烷[4,3-B]吲哚盐酸盐 1,2,3,4,5,6-六氢-9-甲基氮杂卓并[4,5-b]吲哚 1,2,3,4,5,6-六氢-6-甲基氮杂革[4,5-b]吲哚盐酸盐 1,2,3,4,5,6-六氢-3-甲基氮杂卓并[4,5-b]吲哚 (1R*,2E,11S*)-2-(cyclohexylmethylene)-1-(phenylsilyl)methyloctahydropyrrolo[1,2-a]azepine (R)-2-(6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]azepin-9-yl)-acetaldehyde curvulamine (3aR,8aS)-tert-butyl octahydropyrrolo[3,4-d]azepine-2(1H)-carboxylate hydrochloride tert-butyl 6-(2-amino-2-oxoethyl)-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate 3-benzoyl-10-bromo-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 3-(tert-butyloxycarbonyl)-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 1,2,3,4,5,6-hexahydro-3-dimethylaminoethyl-5-hydroxymethylazepino[4,5-b]indole 1,2,3,4,5,6-hexahydro-3-dimethylaminoethyl-5-hydroxymethyl-6-methylazepino[4,5-b]indole (Z)-2,3,9,9a-tetrahydro-6,6-dimethyl-9-methylene-8-vinyl-1H-pyrrolo[1,2-a]azepin-5(6H)-one 2,3,4,5,6,7-hexahydro-1H-3a,8,13,13b-tetraazabenzo[b]cyclopenta[1,2,3-jk]fluorene 2,3,4,5,6,7-hexahydro-1H-3a,8,11,11b-tetraazacyclohepta[1,2,3-jk]fluorene 1-Benzyloxy-2-methoxy-7,8,9,10-tetrahydro-6H-azepino<1,2-a>indole-11-carbaldehyde 3-benzoyl-10-(2-propoxyphenyl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 2-phenyl-2,4,5,6-tetrahydro-1H-6-azabenzo[a]cyclohepta[cd]azulen-1-one 2-carbetoxy-3-(N,N-dimethyl)aminomethyleneamino-8-oxo-8H-4,5,6,7-tetrahydropyrrolo<2,3-c>azepine 3-benzoyl-10-[2-(trifluoromethyl)phenyl]-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 3-benzoyl-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole 6-[2-(4-fluorophenyl)ethyl]-3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one 5-(2-hydroxy-3-morpholin-4-yl-propyl)-3-methyl-4-oxo-1,4,5,6,7,8-hexahydro-pyrrolo[3,2-c]azepine-2-carbaldehyde 6-(2-phenylethyl)-3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one 11-(tert-butyldimethylsilyloxy)-1-trimethylsilyl-3a,4,11,12-tetrahydro-3H-cyclopenta[5,6]azepine[1,2-a]indole-2-one tert-butyl 8,9-dichloro-6-[2-(2,3-dimethylanilino)-2-oxoethyl]-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate tert-butyl 9,10-dichloro-6-[2-(2,3-dimethylanilino)-2-oxoethyl]-1,4,5,6-tetrahydroazepino[4,5-b]indole-3(2H)-carboxylate tert-butyl (1R,4S)-1-(benzylcarbamoyl)-3-oxo-2-((S)-1-phenylethyl)-1,2,3,4,5,10-hexahydroazepino[3,4-b]indol-4-ylcarbamate